A panel of experts formulated consensus guidelines for physicians who use intravenous ketamine infusions to treat chronic pain.
Consensus guidelines regarding the use of ketamine for the management of acute pain have been approved.
Ketamine infusion may provide short-term pain relief for patients with complex regional pain syndrome.
Acute pain management in the emergency department with low-dose ketamine may provide pain relief comparable with morphine at 30 minutes.
Current evidence suggests ketamine may be an effective therapy for the management of chronic noncancer pain.
Ketamine is associated with significant pain relief among patients with refractory headaches.
Ketamine was found to alleviate several pain modalities, and a number of clinical trials investigating its efficacy are ongoing.
Ketamine may alleviate depression, pain, and adverse effects associated with opioid treatment, and may thus represent an attractive adjunct therapy for pain management.
A ketamine regimen is superior to methadone, or ketamine combined with methadone, in alleviating neuropathic pain and associated sensory changes.
A combination of ketamine infusion treatment and psychotherapy was found to attenuate PTSD manifestation and reduce pain scores.
Often, family and friends cannot appreciate the depth of pain and suffering that depression can cause.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Half of Patients Referred for Behavioral Treatment of Migraine Never Initiate Treatment
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness